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Mesomelia-synostoses syndrome (MSS) or mesomelic dysplasia with acral synostoses Verloes-David-Pfeiffer type is a rare autosomal-
dominant disorder characterized by mesomelic limb shortening, acral synostoses, and multiple congenital malformations. So far, ﬁve
patients in four unrelated families have been reported worldwide with MMS. By using whole-genome oligonucleotide array CGH, we
have identiﬁed an interstitial deletion at 8q13 in all patients. The deletions vary from 582 Kb to 738 Kb in size, but invariably encompass
only two genes: SULF1, encoding the heparan sulfate 6-O-endosulfatase 1, and SLCO5A1, encoding the solute carrier organic anion
transporter family member 5A1. SULF1 acts as a regulator of numerous growth factors in skeletal embryonic development whereas
the function of SLCO5A1 is yet unknown. Breakpoint sequence analyses performed in two families showed nonrecurrent deletions.
Real-time quantitative RT-PCR analysis showed the highest levels of SULF1 transcripts in human osteoblasts and cartilage whereas
SLCO5A1 was highly expressed in human fetal and adult brain and heart. Our results strongly suggest that haploinsufﬁciency of
SULF1 contributes to this mesomelic chondrodysplasia, highlighting the critical role of endosulfatase in human skeletal development.
Codeletion of SULF1 and SLCO5A1—which does not result from a low-copy repeats (LCRs)-mediated recombination event in at least
two families—was found in all patients, so we suggest that haploinsufﬁciency of SULF1 combined with haploinsufﬁciency of SLCO5A1
(or the altered expression of a neighboring gene through position effect) could be necessary in the pathogenesis of MSS.Mesomelia-synostoses syndrome (MSS [MIM 600383])—or
mesomelic dysplasia with acral synostoses Verloes-David-
Pfeiffer type1—is a rare clinical entity mainly characterized
by mesomelic limb shortening and acral synostoses, origi-
nally delineated by Verloes and David (1995)2 and inde-
pendently by Pfeiffer et al. (1995).3 MSS is inherited as
an autosomal-dominant trait.2,4 MSS stands apart from
all other mesomelic dysplasias because of the coexistence
with synostoses between metacarpal/metatarsal bones
and carpal/tarsal bones and speciﬁc craniofacial dysmor-
phism (Figure 1). Five patients with MSS have been re-
ported so far, three of whom present with extraskeletal
anomalies including renal malformations and/or congen-
ital heart defects.3,5–7 A report of long-term follow-up of
MSS patients has illustrated the progressive course of
deformation within the mesomelic limb anomalies.4 The
main clinical and radiological features of the patients are
listed in Table 1.
For the last few years, array-based comparative genomic
hybridization (array CGH) has led to the identiﬁcation of
several genes involved in monogenic disorders, such as
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ThePitt-Hopkins syndrome (MIM #610954),9 and MEF2C in
mental retardation (MIM *600662).10 Here, we report the
identiﬁcation by array CGH of a 8q13 microdeletion in
each one of the ﬁve patients withMSS in the four unrelated
families previously reported (Figure 2).2,3,5–7
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Figure 1. Clinical and Radiological Features of Patient II-2 in Family 1
Speciﬁc facial dysmorphy with downslanting palpebral ﬁssures, ptosis, beaked nose, and small mouth (photograph at 15 years of age
reproduced with patient’s permission). Radiograph at 18 months of age of right upper limb showing severe bowing and shortening
of the forearm, metacarpal, carpometacarpal fusions, and brachymetacarpy of the 3rd to 5th ray.genomic imbalance was detected. Deletion size was
different in each of the four unrelated families, ranging
from 582 Kb to 738 Kb (Figure 3 and Table S2). In family
1,2 the proband (I-1) and his affected daughter (II-2) carried
the same deletion at 8q13. Fluorescence in situ hybridiza-
tion (FISH) performed on patient II-2 and his affected
father (I-1) with two probes (the RP11-676B14 BAC clone
located in the 8q13 deleted region and the RP4-585L5
BAC clone as the control probe in the subtelomeric 8p
region) has conﬁrmed the presence of the deletion in
both patients (Figure 4). Normal results were obtained in
the healthy brother (family 1, individual II-1). In families
2,5 3,3 and 4,7 CGH on 44K oligonucleotide arrays showed
normal results for all phenotypically normal parents,
demonstrating that the deletions arose de novo in these
three families. Real-time quantitative PCR (qPCR) with
primers (Table S3) designed inside intron 1 and exon 6 of
SULF1 and introns 2 and 5 of SLCO5A1 were used for
independent conﬁrmation of the array CGH results as
described with minor modiﬁcations.11 Presence of a dele-
tion in all patients and of two normal alleles at 8q13 in
all phenotypically normal parents and the normal brother
in family 1 were conﬁrmed by qPCR (Figure S1).
Genomic disorders are caused by recurrent chromo-
somal rearrangements involving most frequently nonal-
lelic homologous recombination (NAHR) between highly
similar duplicated sequences.12 In contrast, several mecha-
nisms, including nonhomologous end-joining (NHEJ)13 or
fork stalling and template switching (FoSTeS),14 can be
responsible for nonrecurrent rearrangements without the
need for a homologous template or only requiring micro-
homology. By long-range PCR (TaKaRa LA Taq, TAKARA)
and direct sequencing (primer sequences are available
upon request), we characterized the breakpoints at amolec-
ular level in families 1 and 4 (Figure S2). Breakpoint
sequence analyses conﬁrmed that the deletions were
nonrecurrent in these two families. The deletion in family
4 may have been mediated by NHEJ whereas a more
complex rearrangement was observed in family 1. The vari-
able size of the deletions and the absence of segmental
duplications at the breakpoint junctions indicate that
MMS is not a genomic disorder associated with deletions96 The American Journal of Human Genetics 87, 95–100, July 9, 2010recurring from NAHR in at least two families. To our
knowledge, this microdeletion has never been associated
with any other disease. None of the deletions identiﬁed
here have been reported in the Database of Genomic Vari-
ants nor in our cohort of patients with mental retardation
analyzed by array CGH (n¼ 850; unpublished data). These
observations demonstrate that the 8q13 deletions are
responsible for MSS.
SULF1 contains 23 exons and shares about 64%homology
with its ortholog SULF2 and93% identitywith itsmurinepa-
ralog Sulf1. Heparan sulfate 6-O-endosulfatases, such as
SULF1, modulate the function of heparan sulfate by altering
binding sites for signaling molecules. They regulate the
activity of growth factors such as bone morphogenetic
proteins (BMPs),15 ﬁbroblast growth factors (FGFs),16 and
Wnt ligands17 and thus control important developmental
processes such as cell growth and differentiation. Sulf1 is ex-
pressed in most adult mouse tissues, highest levels being
observed in bone, testis, stomach, skeletal muscle, lung,
and kidney.18 During mouse embryonic development,
Sulf1 is widely expressed in the forelimb, arm girdle, the
condensing mesenchyme in the distal limb buds, the carti-
laginous parts in digits, the brain, somites, clefts of the bran-
chial arches, eyes, palate, tongue, and nasal pits.18,19 The
expression pattern of Sulf1 during embryonic development
overlaps the dysostoses andmalformations observed inMSS.
The role of Sulf1 and Sulf2 during embryonic develop-
ment has been studied in two sulfatase-deﬁcient mouse
models. Surprisingly, targeted disruption of Sulf1 or Sulf2
leading to a profound loss of expression of the Sulf1 or
Sulf2 proteins exhibited only subtle skeletal anomalies,
such as mild forms of dorsally split vertebrae in Sulf1
mutants.19 In contrast, mice deﬁcient in both Sulf1 and
Sulf2 exhibited increased perinatal lethality and develop-
mental defects, including skeletal and renal abnormalities.
Holst et al. (2007)18 showed that double mutant Sulf1 and
Sulf2 embryos exhibited altered cartilage zonation in the
ulna and radius and a decrease in bone volume and length
in the axial and appendicular skeleton. In a second sulfa-
tase-deﬁcient mouse model, Ratzka et al. (2008)19 showed
that double mutants for Sulf1 and Sulf2 exhibited skeletal
anomalies such as reduced bone length, premature
Table 1. Clinical and Radiological Features in Patients with
Mesomelia-Synostosis Syndrome
Patient F.1 I-1 F.1 II-2 F.2 II-3 F.3 II-1 F.4 II-1
Polyhydramnios NA - þ - þ
Craniofacial
Palpebral ﬁssures
downslanted
þ þ þ þ þ
Eyelid ptosis þ þ þ þ þ
Telecanthus þ þ 5 þ þ
Hypoplasia soft palate;
absent uvula
þ þ þ þ þ
Mild micrognathia þ þ þ þ þ
Short sublingual frenula;
excess frenula
þ þ NA NA NA
Cognitive and Sensory Functions
Developmental delay - - - - -
Speech with nasal quality þ þ þ þ þ
Myopia þ þ - - -
Hearing deﬁcit þ - - - -
General Physical Features
Short stature þ þ þ þ þ
Complex congenital heart
defect
- - þ - þ
Umbilicus; short cord;
excess skin; hernia
þ þ - NA þ
Congenital
hydronephrosis
NA - þ þ þ
Limited motion in joints þ þ þ þ þ
Mesomelic bowing and
shortening in both upper
and lower limbs
þ þ þ þ þ
Complex brachydactyly
(postaxial)
þ þ þ þ þ
Ulnar deviation of hands þ þ þ þ þ
Narrow, short feet þ þ þ þ þ
Brachydactylic toes
(ﬁbular side)
þ þ þ þ þ
Dysfunctional ankle
joints
þ þ þ þ þ
Radiological Features
Proximal carpometacarpal
fusion
þ þ þ þ þ
Shortened phalanges þ þ þ þ þ
Mild bowing of distal part
of femora
þ þ þ þ -
Medial bowing tibial
diaphyses
þ þ þ þ þ
Shortened metatarsals þ þ þ þ -
Tarsometatarsal
synostoses
þ þ þ þ þ
Notation is as follows: þ, present; -, absent; F., family; NA, not available.
Figure 2. Pedigrees of the Families with Mesomelia-Synostoses
Syndrome
The families 1, 2, 3, and 4 were reported by Verloes and David
(1995),2 Leroy et al. (2001),5 Pfeiffer et al. (1995),3 and Day-Salva-
tore and McLean (1998),7 respectively. The arrows indicate the
probands. þ/del indicate the presence of heterozygous 8q13 dele-
tion. þ/þ indicate the presence of two copies of the 8q13 region.
NA, DNA sample not available.
Thevertebrae ossiﬁcation, and fusion of sternebrae and tail
vertebrae. In the mouse, loss of increasing numbers of
sulfatase alleles enhances severity and penetrance of the
skeletal alterations and leads to malformations at addi-
tional sites. Overall, these murine phenotypes strongly
suggest that SULF1 haploinsufﬁciency plays a key role in
the skeletal abnormalities in patients with MSS. However,
compositional analysis by RPIP-HPLC of heparan sulfate20
recovered from the urine of patient II-2 of family 1 revealed
no abnormalities in heparan sulfate structure (Figure S3).
The role of SULF1 in human carcinogenesis is under
active investigation. SULF1 inhibits the coreceptor func-
tion of heparan sulfate proteoglycans (HSPGs) in multiple
receptor tyrosine kinase signaling pathways. SULF1 also
promotes drug-induced apoptosis of cancer cells in vitro
and inhibits tumorigenesis and angiogenesis in vivo.21
None of the patients with the SULF1 deletions presented
with any type of tumor.
We have identiﬁed nonrecurrent deletions in all
analyzed patients, invariably including both SULF1 and
SLCO5A1. For most monogenic diseases resulting from
haploinsufﬁciency, point mutations are identiﬁed in the
majority of patients whereas genomic deletions are only
rarely detected. Because nonrecurrent deletions have
been found in the four known families and do not result
from NAHR in at least two families, the hypothesis that
the deletions were observed by chance is unlikely.
An alternative hypothesis is that haploinsufﬁcency of
SULF1 is necessary but not sufﬁcient: expression of MSS
phenotype would require an additional effect, either
through the deletion of SLCO5A1 or through an alteration
of the expression of neighboring gene(s) by position effect.
In such case, (1) SULF1 haploinsufﬁciency might cause the
skeletal phenotype while additional gene(s) would explainAmerican Journal of Human Genetics 87, 95–100, July 9, 2010 97
Figure 3. Array-CGH Profiles at 8q13
The 400K oligonucleotide arrays performed on patients from families 1, 2, 3, and 4 were analyzed with the Agilent scanner and the
Feature Extraction software (v. 9.1.3). For each patient, positive and negative log2 ratio values are depicted by green and red vertical
bars, respectively. Deleted segments are highlighted in gray whereas black vertical bars delimit the minimal deleted interval. RefSeq
genes (including SULF1 and SLCO5A1) are indicated in blue. The black box at the bottom indicates the BAC probe RP11-676B14, which
was used by FISH validation. Note that ﬁve noncoding RNA pseudogenes are predicted or present in the deleted regions.the other abnormalities such as the cardiac or renal defects
or (2) the entire phenotype might be due to epistasis
between SULF1 and SLCO5A1 or neighboring gene(s), as
suggested by the mild phenotype observed in Sulf1mutant
mice.18,19
SLCO5A1 encodes a protein with 12 transmembrane
domains. It is a member of the solute carrier organic anion
transporter superfamily. Both expression pattern and func-
tion of SLCO5A1 are still unknown. Among previously
reported copy number variants (CNVs) at 8q13, only one
partial deletion of SLCO5A1 has been identiﬁed in a single
normal individual.22 This may suggest that the deletion of
this gene alone is unlikely to be responsible for MSS.
We have performed expression analyses for SULF1 and
SLCO5A1 with total RNA extracted from different human
tissues. Both adult and fetal RNAwere obtained from brain,
heart, kidney, and liver tissues (Clontech). Primary human
osteoblasts were isolated from bone explants23 and human
osteoclasts were differentiated from puriﬁed CD14þ cells.24
Healthy cartilage was harvested from patients referred to
the Department of Orthopaedic Surgery during operations
for intramedullary nail removal. Total RNA was extracted
according to the previously described procedure.25 Real-98 The American Journal of Human Genetics 87, 95–100, July 9, 2010time quantitative reverse transcription PCR (qRT-PCR)
was performed via the DDCt method11 and two house-
keeping genes (Table S4). SULF1 was highly expressed in
adult osteoblasts and cartilage and moderately so in fetal
kidney and brain (Figure 5A). SLCO5A1 was highly ex-
pressed in fetal and adult brain and heart (Figure 5B).
In conclusion, we have shown that MSS is caused by a
8q13 microdeletion, enclosing only the genes SULF1 and
SLCO5A1. Deletion of SULF1 is the more likely culprit of
at least the skeletal abnormalities in MSS. Because it was
combined with SLCO5A1 deletion in all pedigrees, we
hypothesize that MSS could either result from the com-
bined haploinsufﬁciency of both genes or be the result of
SULF1 haploinsufﬁciency associated with altered expres-
sion of a neighboring gene through position effect. Our
observation may point to a possible role of SULF1 and/or
SLCO5A1 as the cause of one or more other rare mesomelic
dysplasias. The Kantaputra mesomelic dysplasia (MIM
156232) is one example of these mesomelic dysplasias
withunknownmolecular basis.Wehavedirectly sequenced
the coding regions and surrounding exon/intron bound-
aries in SULF1 and SLCO5A1 (Table S5) in two patients
with Kantaputra typemesomelic dysplasia26,27 and studied
Figure 4. FISH Analysis
Dual-color FISH analysis was performed on metaphases of patient
II-1 of family 1 via the RP11-676B14 BAC probe in the 8q13 dele-
tion and a subtelomeric 8p probe (RP4-585L5) used as a control
(labeled with SpectrumOrange and SpectrumGreen, respectively).
The arrow indicates the deletion.the genomic region by 44K oligonucleotide array. We did
not identify any deleterious point mutations in these two
genes nor any deletion and/or duplication at 8q13 or else-
where in the genome. More patients with this or other
less-well-delineated mesomelic dysplasias need to be inves-
tigated in order to further address the speciﬁcity of the
correlation between the deletion 8q13 and MSS.Figure 5. Expression Patterns of SULF1 and SLCO5A1 in a Panel of
cDNA were obtained via the MMLV reverse transcriptase (Invitrogen)
and four fetal tissues and two cultured cells (osteoblasts and osteocl
premix on Light Cycler 480 (Roche diagnostics). The DDCt method
(A) and SLCO5A1 (B)—relative to the expression level of the GAPDH
was compared to the median of the DCt of the 11 tissues analyzed. As
the different tissues with the same method and showed minor differ
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